Alzheimer's Association Applauds European Medicines Agency Decision to Recommend Leqembi for the Treatment of Alzheimer's Disease
November 15, 2024
November 15, 2024
CHICAGO, Illinois, Nov. 15 -- The Alzheimer's Association issued the following news release on Nov. 14, 2024:
The Alzheimer's Association welcomes today's decision by the European Medicines Agency (EMA) to recommend the approval of Leqembi(R) (lecanemab) for marketing in Europe. Today's action is a reversal of the agency's negative July decision.
"This is an important step toward Europeans having access to a proven treatment that changes the underlying course of Al . . .
The Alzheimer's Association welcomes today's decision by the European Medicines Agency (EMA) to recommend the approval of Leqembi(R) (lecanemab) for marketing in Europe. Today's action is a reversal of the agency's negative July decision.
"This is an important step toward Europeans having access to a proven treatment that changes the underlying course of Al . . .